Menotrophin Ferring-Léčiva (Menotrophin)

The product provides exogenous follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. FSH promotes growth of ovarian follicles, while LH supports steroid production and final maturation, together mimicking the natural pituitary surge that leads to ovulation.

The dose of Menotrophin is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s ovarian response, treatment protocol and clinical goals. No fixed regimen is provided in public information.

Menotrophin is intended for use before conception and is not indicated for treatment during pregnancy. Safety data for use while breastfeeding are lacking, so the product should be avoided in nursing mothers unless the prescriber decides the benefits outweigh potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Menotrophin contains a fixed combination of FSH and LH, whereas some alternatives provide only FSH (e.g., recombinant FSH) or separate LH preparations. The combined formulation can simplify dosing for protocols that require both hormones, but clinicians may choose other products based on specific patient characteristics, cost or regulatory considerations.

Menotrophin must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Menotrophin is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or a patient who has been instructed on proper aseptic technique and dose preparation.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause fluid accumulation, thrombosis, and organ dysfunction, as well as the possibility of multiple pregnancy and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if these events are suspected.

Menotrophin is contraindicated in patients with known hypersensitivity to menotropins or any excipients, in those with active ovarian cysts, uncontrolled thyroid disease, or a history of severe ovarian hyperstimulation syndrome. It should also be avoided in pregnant women and is not recommended for use in patients with uncontrolled endocrine disorders without specialist supervision.